ReviewAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026
The Future of the HIV Response: Sustaining Progress in an era of Political Uncertainty and Scientific Opportunity.
Review in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Special Issue on New Horizons in HIV and Reproductive Health Research.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- The Future of the HIV Response: Sustaining Progress in an era of Political Uncertainty and Scientific Opportunity.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global HIV response is at a pivotal juncture. The field is experiencing a paradox: rapid scientific innovation alongside increasing fragility in financing, political commitment, and implementation systems. Significant progress has been made in expanding access to HIV treatment and prevention, but major gaps in coverage and equity existed previously, that were further exacerbated and destabilized by changes in US government support in January 2025. This commentary examines the implications of this divergence and argues that the future of the HIV response depends less on new biomedical discoveries than on the capacity to deliver existing and emerging options sustainably and with speed, scale and equity. Drawing on recent advances in HIV prevention and treatment, as well as massive disruptions and cuts in both global health programs, including PEPFAR, and biomedical research funding under the new US Presidential Administration, the paper identifies key priorities for the next phase of the response, including strengthening health systems, ensuring equitable access, re-centering community leadership, and securing long-term political and financial commitments. Without decisive action, the gains of the past four decades risk stagnation or, worse, actual reversal; with it, the goal of ending the HIV epidemic may still be achievable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.